CER “Substantial Impact” Expected in Three-to-Five Years: NPC’s Annual Comparative Effectiveness Survey
This article was originally published in RPM Report
Executive Summary
CER is slowly beginning to enter the public lexicon. Respondents to the National Pharmaceutical Council annual survey on comparative effectiveness report being more familiar with CER now than two years ago; but they still see the major impact several years away – not right on the horizon.
You may also be interested in...
Sliding Perception Of CER Importance Not Concerning To PCORI’s Selby
PCORI Executive Director Joe Selby says decline in perception that comparative effectiveness research is “very important” to stakeholders in annual National Pharmaceutical Council survey “makes sense,” adding that results offer a realistic appraisal of expectations on the future of CER.
The State of CER: Some Progress, Cautious Optimism
It isn’t a household name—yet—but the Patient-Centered Outcomes Research Institute has certainly increased its name recognition among health care stakeholders during the last year, especially as it works to meet the federally mandated requirements of the Affordable Care Act. This was just one of the findings by the National Pharmaceutical Council from the second year of surveying key stakeholders about comparative effectiveness research (CER) perceptions and its impact on health care decisions.
State of Comparative Effectiveness Research: Benchmark Survey
Comparative Effectiveness Research is a phrase with talisman qualities inside the Beltway -- ascribed with almost magical properties to improve product/treatment choices and drive down health care expenditures. Outside the political sphere, the meaning of the term and concepts about how to effect CER are less clear.